Today: 18 January 2026
Subscribe
Browse Category

Biotech News 17 June 2025 - 18 August 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

New Drug Approvals & Clinical Trial Results Mergers, Acquisitions & Partnerships (No other major M&A deals were announced during Aug 17–18, but this Lilly-Superluminal alliance highlights the continued investment in AI-driven R&D.) Regulatory & Policy Updates Public Health & Epidemiology (No major new COVID-19 variant or pandemic threat emerged over the weekend, but health officials continue to monitor familiar foes…
18 August 2025
·
Tech Titans Face Off, Rockets Soar, and Biotech Breakthroughs – Tech News Roundup (Aug 17–18, 2025)

Tech Titans Face Off, Rockets Soar, and Biotech Breakthroughs – Tech News Roundup (Aug 17–18, 2025)

Smartphones & Gadgets: Pixel Teasers and iPhone Rumors Cybersecurity: Telecom Ransomware Shock Space & Aerospace: Record Launches and New Missions Biotech & Health Tech: New Cures and Big Deals Tech Policy & Regulation: Trade Tensions and Antitrust Fines Autos & Mobility: Carmaker Alliances and EV Moves Sources: Reuters, Spaceflight Now, TechRadar, PhoneArena, MacRumors, TS2 Technology Techradar Techradar Reuters Reuters Reuters Cybernewscentre…
18 August 2025
····
Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

For the period August 16–17, 2025, the biotech, pharma, medical, and health sectors saw a range of significant developments worldwide. Below is a comprehensive roundup of top stories categorized by theme, complete with expert insights and source links: Clinical Trial Results & Study Readouts Drug & Device Approvals Mergers, Acquisitions & Partnerships Public Health Alerts Research & Medical Breakthroughs Healthcare…
17 August 2025
··
Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

Breakthroughs in Biotech & Pharma Big Deals & Industry Moves Regulatory & Health Policy Updates Public Health Developments Noteworthy Medical Research Healthcare Technology & Innovation Sources: Original news reports, press releases and scientific publications from Aug 14–15, 2025 Fda Fiercebiotech Fiercepharma Paho Fiercebiotech, as cited above. Each development is attributed to reputable sources including FDA announcements, company press statements, peer-reviewed…
15 August 2025
··
Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Breakthroughs in Biotech & Pharma Big Deals & Industry Moves Regulatory & Health Policy Updates Public Health Developments Noteworthy Medical Research Healthcare Technology & Innovation Sources: Official press releases, government health agency updates, and reputable media coverage were used in this report (including Reuters, Fierce Biotech/Pharma, Bloomberg, FDA/CDC/DSHS releases, and peer-reviewed journals). All source links are provided inline above for…
14 August 2025
·
Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

IO Biotech’s Phase 3 melanoma vaccine Cylembia added to Merck’s Keytruda narrowly missed statistical significance, with median progression-free survival of 19.4 months versus 11 months for Keytruda alone. Fosun Pharma’s deal with Expedition Therapeutics grants rights outside Greater China to XH-S004, a first-in-class oral DPP-1 inhibitor for chronic respiratory diseases, in a pact potentially worth up to $645 million including…
12 August 2025
·
Breakthrough Cures, Big Pharma Shake-Ups & Health Policy Bombshells – Biotech/Health News (Aug 7–8, 2025)

Breakthrough Cures, Big Pharma Shake-Ups & Health Policy Bombshells – Biotech/Health News (Aug 7–8, 2025)

Scientific Breakthroughs & Discoveries (Aug 7–8, 2025) Regulatory Updates (FDA and Other Agencies) Mergers, Acquisitions & Financial News Public Health & Policy Updates Sources: The information above is sourced from recent press releases, regulatory announcements, and news reports between Aug 7–8, 2025, including Scripps Research Eurekalert Eurekalert, EurekAlert! Eurekalert, Boston Globe Kffhealthnews Bostonglobe, UC Davis Health News Ucdavis Ucdavis, U.S. FDA…
8 August 2025
Top 10 Tech Trends Exploding in 2025: Generative AI, Quantum Leaps, Biotech Breakthroughs & More

Top 10 Tech Trends Exploding in 2025: Generative AI, Quantum Leaps, Biotech Breakthroughs & More

In 2025, enterprise adoption of generative AI doubled to 65% of organizations, with 92% of Fortune 500 companies leveraging OpenAI’s technology. In June 2025 IBM announced fault-tolerant quantum error-correction progress and unveiled Starling, a 200-logical-qubit machine (~10,000 physical qubits) planned to be operational by 2029. CRISPR-based therapies for blood disorders are expected to receive regulatory approval by 2025. By mid-2025,…
17 June 2025
···
1 … 10 11 12

Stock Market Today

  • Live Oak Bancshares (LOB) Valuation After Recent Share-Price Swings
    January 18, 2026, 12:03 PM EST. Live Oak Bancshares (LOB) trades at $37.60, after volatile moves that produced a 90-day return of 10.26%, a 1-year total shareholder return of -7.18% and a 3-year gain of 23.24%. The latest analysis flags upside potential, with a narrative fair value around $42.00. That implies the stock is undervalued, though the upside hinges on sustained growth in new verticals and the ability to sell government-guaranteed loans at premiums, which can diversify revenue and support earnings. Traditional checks tell a tighter story: the stock trades at a P/E of 25.1x versus 15.8x for peers and 11.9x for the broader US Banks industry, above the firm's 21.2x target. Risks include heavy reliance on government-backed lending and ongoing digital investment costs that could pressure margins if results disappoint.
Go toTop